We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction.
- Authors
Miró, E; del Cuerpo, M; Navarro, F; Sabaté, M; Mirelis, B; Prats, G
- Abstract
Between 1994 and 1996 we detected 28 out of 7054 (0.4%) clinical isolates of Escherichia coli with abnormal or reduced inhibition diameters to co-amoxiclav and ceftazidime in a disc diffusion test. The increased MIC of ceftazidime (1-32 mg/L) and the effect of synergy between this antibiotic and co-amoxiclav according to the disc diffusion test suggest the presence of an extended-spectrum β-lactamase. However, enzymatic characterization and the nucleotide sequence confirm the hyperproduction of the SHV-1 enzyme.
- Subjects
SPAIN; DNA analysis; COMBINATION drug therapy; COMPARATIVE studies; ELECTROPHORESIS; ENZYME inhibitors; ESCHERICHIA coli; HYDROLASES; RESEARCH methodology; MEDICAL cooperation; MICROBIAL sensitivity tests; POLYMERASE chain reaction; PULSED-field gel electrophoresis; RESEARCH; EVALUATION research; SEROTYPING; CEFTAZIDIME; PHARMACODYNAMICS
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 1998, Vol 42, Issue 4, p535
- ISSN
0305-7453
- Publication type
journal article
- DOI
10.1093/jac/42.4.535